跳转至内容
Merck
CN

28-3740

磷酸钠 二元 十二水合物

99.0-100.5%, suitable for oxidant determination

别名:

磷酸氢二钠, 磷酸氢二钠 十二水合物

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:
Na2HPO4 · 12H2O
化学文摘社编号:
分子量:
358.14
UNSPSC Code:
12352300
PubChem Substance ID:
EC Number:
231-448-7
MDL number:
Assay:
99.0-100.5%
Grade:
SAJ special grade
Form:
crystalline
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

SAJ special grade

assay

99.0-100.5%

form

crystalline

availability

available only in Japan

pH

8.4-9.6 (25 °C, 35.8 g/L)

suitability

suitable for oxidant determination

SMILES string

O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

InChI

1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2

InChI key

DGLRDKLJZLEJCY-UHFFFAOYSA-L



Still not finding the right product?

Explore all of our products under 磷酸钠 二元 十二水合物


存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
Yuichiro Yano et al.
Journal of the American College of Cardiology, 65(4), 327-335 (2015-01-31)
Isolated systolic hypertension (ISH), defined as systolic blood pressure (SBP) ≥140 mm Hg and diastolic blood pressure (DBP) <90 mm Hg, in younger and middle-aged adults is increasing in prevalence. The aim of this study was to assess the risk
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2